| BLINATUMOMAB (BLINCYTO®) PRESCRIBER ORDER FORM | | | | | | |
|---|----------------------------------|--|---|---------------------|------------------------|------------|
| Fax completed form, insurance information, and clinical documentation to: | | | | | | |
| | Patient Name: | | | Da | Date of Birth: | |
| option care health | Address: | | | | | |
| option care nearth | Phone: | | Height: | ☐ inches ☐ cm | Weight: | ☐ lbs ☐ kg |
| Clinical Information | | | | | | |
| Primary Diagnosis De | escription: | ICD-10 Code: | | | | |
| Blinatumomab (Blincyto®) Prescription | | | | | | |
| Blinatumomab (Blincyto®) ☐ Infuse 28 mcg/day IV continuously via ambulatory pump (patient weight ≥ 45 kg). | | | | | | |
| ☐ Infuse 15 mcg/m²/day () IV continuously via ambulatory pump (patient weight < 45 kg). | | | | | | |
| Current cycle number: Date current cycle initiated: Start day of 28-day cycle. | | | | | | |
| Medicare Orders: E0781 Ambulatory Infusion (1 per month), A4222 IV Admin Kit (1 per bag/cassette), A4221 IV supplies (1 per week) | | | | | | |
| Ancillary Orders | | | | | | |
| Medication Orders | | | | | | |
| Patients Weighing ≥ 45 kg (Select one of the following): | | | | | | |
| Dexamethasone 20 mg IV one hour before 1st dose of each new cycle (relapsed/refractory). Dexamethasone 16 mg IV one hour before 1st dose of each new cycle. Solu-Cortef® 400 mg IV one hour before 1st dose of each new cycle. Methylprednisolone 80 mg IV one hour before 1st dose of each new cycle. | | | | | | |
| Patients Weighing < 45 kg: | | | | | | |
| Dexamethasone (5 mg/m 2 – max 20 mg) IV one hour before 1 st dose of each new cycle. | | | | | | |
| Other: | | | | | | |
| ☐ Other: IV Flush Orders [Do not flush in between blinatumomab (Blincyto®) bag changes.] | | | | | | |
| ☐ PICC and Central Tunneled/Non-Tunneled: NS 5 mL pre-lab draw and 10 mL post-lab draw. For maintenance, heparin ☐ (10 | | | | | | in □ (10 |
| ☐ Implanted | · | unit/mL) 5 | unit/mL) 5 mL \underline{or} (100 unit/mL) 3 mL every 24 hr to non-medication lumen. When appropriate, NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab dr | | | men. |
| | | Heparin (100 unit/mL) 3 to 5 mL post-use at completion of cycle. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed and not used for medication or | | | | |
| weekly to monthly if not accessed. Lab Orders | | | | | | |
| □ No labs ordered at this time. | | | | | | |
| | | | | | | |
| Other: Blinatumomab (Blincyto®) bag changes as required by infusion nurse until patient and/or caregiver trained to independent with bag | | | | | | |
| changes. Infusion no | t to be interrupted > 4 hours. | | | | • | |
| I certify | that the use of the indicated tr | eatment is medi | ically necessary and I | will be supervising | the patient's treatmer | ıt. |
| Prescriber Signature: Date: | | | | | | |
| Prescriber Information | | | | | | |
| Prescriber Name: | | | Phone: | F | ax: | |
| Address: | | | NPI: | | | |
| City, State: Z | | Zip: | Office Contact: | | | |

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.